UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
AC Immune reported positive week-100 results from VacSYn Part 1 on September 23, 2026. Safety, tolerability and immunogenicity endpoints were met; clinical benefit remains unproven. FDA discussions on the expanded Phase 2 design are planned for early 2027. Cash resources remain the reported CHF 75.4 million at June 30, with management’s August funding estimate into Q4 2027 excluding potential milestones.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
Part 1 results released. Next development step: FDA discussions on the Part 2 design, expected early 2027; no exact meeting date or Part 2 start date announced. ACI-19764: initial cardiovascular-risk data around year-end; full Phase 1/1b results H1 2027.
EGM held October 2, 2026: shareholders approved Tom Graney’s board election through the end of AGM 2027. This governance outcome is separate from clinical development. October 2 Form 6-K
Week-100 safety and immunogenicity findings support continued VacSYn development. The constructive case now depends on a credible Part 2 design and subsequent clinical evidence, supported by an executable financing plan.
The dataset comprises 25 treated patients and nine placebo recipients. Exploratory biomarker correlations do not establish clinical efficacy. FDA alignment, trial execution and financing remain material uncertainties.
VacSYn Part 1 met its primary safety, tolerability and immunogenicity endpoints at week 100. The 34-patient dataset supports further investigation, while biomarker and clinical findings remain exploratory. Part 2 is intended to assess clinical activity before a Phase 3 decision.
AC Immune SA is a clinical-stage biopharmaceutical company based at the EPFL Innovation Park in Lausanne, Switzerland, listed on Nasdaq since 2016 and reporting in Swiss francs under international accounting standards. It designs active immunotherapies, which are vaccines that train a patient’s own immune system to produce antibodies against a misfolded protein, and small molecules aimed at the same targets. The proteins in question are alpha-synuclein in Parkinson’s disease, amyloid beta and phosphorylated Tau in Alzheimer’s disease, TDP-43 in amyotrophic lateral sclerosis, and the NLRP3 inflammasome, which sits upstream of neuroinflammation in several of these diseases.
The business combines wholly owned candidates, including ACI-7104, ACI-19764 and ACI-19626, with Alzheimer’s programs partnered with Takeda, Lilly and Janssen. Partner payments provide non-dilutive funding, but both owned and partnered programs carry clinical and commercial uncertainty. Contract revenue is not product sales.
On August 11, 2026 the U.S. Food and Drug Administration granted Fast Track designation to ACI-7104 for early-stage Parkinson’s disease and cleared the company’s Investigational New Drug application. The two decisions arrived together and do different things. The IND clearance is the operative one: it allows the ongoing Phase 2 VacSYn trial, whose registry version posted October 1, 2026 lists twelve European sites across Germany, Spain and the United Kingdom, to open sites in the United States. Fast Track is a process designation that permits more frequent written and oral communication with the agency and makes a submission eligible for rolling review and, if the criteria are met at the time, for accelerated approval or priority review. Neither decision is evidence that the drug works, and neither shortens the trial.
Shareholders approved the election through the end of AGM 2027. Minutes are to be published within 15 days; no vote tally or separate committee appointment is supplied in this filing.
Positive safety and immunogenicity results; clinical observations remain exploratory. FDA talks on Part 2 planned for early 2027.
Historical September 3 announcement: Tom Graney’s election was proposed and Carl June’s departure was to become effective at the EGM. The October 2 Form 6-K now confirms that shareholders approved Graney’s election; the voting result is reported separately below.
The first NLRP3 analysis is now available. Remaining development milestones are updated below.
US expansion was permitted for ACI-7104. The then-guided H2 2026 Part 1 readout was subsequently reported on September 23.
The full deep dive has the answer’s building blocks: cash, dilution, catalysts and risks, every figure sourced.
Free. No signup. You decide, we don’t recommend.
The detailed biomarker and safety figures discussed below refer to the December 2025 interim analysis. The September 23 week-100 update is summarized at the end of this section; it does not newly quantify every interim signal.
What follows is the argument as its holders make it, not a Merlintrader view.
Immunogenicity supports further investigation. Interim antibody responses in serum and CSF support biological activity. They do not establish a clinical benefit, superiority to passive antibodies or the disappearance of competitive risk.
The safety profile is what an active immunotherapy needs. The theoretical objection to vaccinating against a normal human protein is autoimmunity. Across weeks 50 and 76 there were no clinically relevant or serious adverse events considered drug related, and the common events were injection-site reactions, headache and fatigue. That profile supports the long dosing intervals and the multi-year follow-up the Goradia grant now funds.
Three biomarkers moved in the same direction. CSF alpha-synuclein stabilised, neurofilament light stabilised where placebo rose, and plasma GFAP and DaT-SPECT both pointed the same way. Consistency across independent measures is harder to explain by chance than a single positive marker, which is the point Professor Poewe made when he called the consistency of the trends remarkable.
Regulatory access has improved. Fast Track offers additional opportunities for FDA interaction, and IND clearance permits US expansion. An agreed registrational design and the timing of any future approval remain unconfirmed.
Someone else pays for the Alzheimer’s half. Takeda funds ACI-24, Lilly funds the Tau small molecules, Janssen holds ACI-35. That structure produced CHF 16.2 million of first-half revenue, a $100.0 million upfront in 2024 and a $12.0 million milestone in April 2026, and it is why the share count has grown about 1.3% a year rather than the double digits typical of a company at this stage.
Partnership optionality remains relevant. Further milestones or a new agreement could extend funding, but contingent payments are not available cash. Market capitalisation less historical cash is not a standalone valuation of the pipeline.
Week-100 safety and immunogenicity findings support continued VacSYn development. The constructive case now depends on a credible Part 2 design and subsequent clinical evidence, supported by an executable financing plan.
Thirty-four patients. Part 1 randomised 34 people three to one, with 25 treated patients and nine placebo recipients, as confirmed on September 23. Every biomarker and clinical comparison rests on that comparator. Trends that look clean at this size have repeatedly failed to replicate in Parkinson’s disease, where symptomatic variability is large and progression over eighteen months is modest even in untreated patients.
The efficacy analysis that matters most is post-hoc. The stabilisation of total CSF alpha-synuclein carries a p value of 0.018 from a post-hoc analysis. An analysis specified after seeing the data is a hypothesis, not a result, and regulators treat it accordingly.
The primary endpoints are not efficacy endpoints. VacSYn’s primary endpoints are safety and antibody titres. The clinical measure that would matter to a patient, MDS-UPDRS Part III, is secondary and the study was not designed to power it. A readout can therefore be reported as successful while leaving the central commercial question open, and the market may not price that distinction consistently.
The readout has now arrived. December 2025 guidance pointed to mid-2026, followed by H2 2026 guidance in August. The September 23 release reports the complete Part 1 dataset explicitly at week 100, resolving the current timing question despite the week-104 description in the August 5 document. The remaining uncertainty is the design, initiation and clinical outcome of Part 2; FDA meetings are expected in early 2027, not confirmed for a particular day.
The company is being run on an interim basis. The founder chief executive retired at the June 11, 2026 annual general meeting and the chair holds the executive seat while a search continues. The registrational strategy, any partnering of ACI-7104 and any financing decision fall inside that interval.
Further development may require additional capital. Management estimates funding into Q4 2027. A larger or longer trial could require partnership proceeds, equity or another financing source; the amount and timing depend on a development plan that has not been established here.
Partner money can stop. Takeda may terminate the option and licence agreement at any time on ninety days’ notice. The revenue line that carried the first half of 2026 is composed of two non-recurring payments from two counterparties, and there is no product revenue underneath it.
Currency and disclosure timing matter. Swiss-franc results require dated conversion for dollar comparisons. AC Immune provides interim corporate and financial updates in addition to its formal annual and half-year statements; investors should consult new 6-K filings rather than assume a fixed two-release calendar.
The central risk after the readout: favorable safety and antibody responses from 25 treated patients against nine placebo recipients do not establish disease modification. A larger clinical evaluation and a fundable development plan are still needed, with interim leadership and management-estimated funding into Q4 2027.
The two paths below are descriptions of what would have to happen, not forecasts, and they carry no probabilities and no price levels.
The constructive scenario would combine sustained VacSYn findings with a credible next-stage development plan, evidence of anti-inflammatory activity in the ongoing NLRP3 cohort, and adequate financing. These are conditional outcomes, not forecasts. A permanent leadership appointment and continued partner progress would add execution visibility.
The difficult scenario involves weaker clinical signals, delays or safety findings, together with financing on less favourable terms. Positive early tolerability does not rule out later problems. Partnership terms differ by agreement; the Takeda termination provision must not be generalised to every counterparty.
The main distinction is whether biological signals translate into reproducible, clinically meaningful outcomes and a fundable development plan. See the catalyst section for current windows. Merlintrader has found no confirmed date for the next earnings release; the March 13, 2026 release concerned FY2025, not FY2026.
The dataset comprises 25 treated patients and nine placebo recipients. Exploratory biomarker correlations do not establish clinical efficacy. FDA alignment, trial execution and financing remain material uncertainties.
In Merlintrader’s reading, AC Immune is a company funded by other people’s milestones while it tries to show that an active immunotherapy can do something in Parkinson’s disease. Each of the following would contradict that reading directly, and each is checkable against a primary document.
None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.
AC Immune SA is a clinical-stage biopharmaceutical company based at the EPFL Innovation Park in Lausanne, Switzerland, listed on Nasdaq since 2016 and reporting in Swiss francs under international accounting standards. It designs active immunotherapies, which are vaccines that train a patient’s own immune system to produce antibodies against a misfolded protein, and small molecules aimed at the same targets. The proteins in question are alpha-synuclein in Parkinson’s disease, amyloid beta and phosphorylated Tau in Alzheimer’s disease, TDP-43 in amyotrophic lateral sclerosis, and the NLRP3 inflammasome, which sits upstream of neuroinflammation in several of these diseases.
The business combines wholly owned candidates, including ACI-7104, ACI-19764 and ACI-19626, with Alzheimer’s programs partnered with Takeda, Lilly and Janssen. Partner payments provide non-dilutive funding, but both owned and partnered programs carry clinical and commercial uncertainty. Contract revenue is not product sales.
On August 11, 2026 the U.S. Food and Drug Administration granted Fast Track designation to ACI-7104 for early-stage Parkinson’s disease and cleared the company’s Investigational New Drug application. The two decisions arrived together and do different things. The IND clearance is the operative one: it allows the ongoing Phase 2 VacSYn trial, whose registry version posted October 1, 2026 lists twelve European sites across Germany, Spain and the United Kingdom, to open sites in the United States. Fast Track is a process designation that permits more frequent written and oral communication with the agency and makes a submission eligible for rolling review and, if the criteria are met at the time, for accelerated approval or priority review. Neither decision is evidence that the drug works, and neither shortens the trial.
The financial position is a small one, held together by partner payments. Total cash resources were CHF 75.4 million at June 30, 2026, about $93.0 million at the August 11 exchange rate, composed of CHF 27.8 million of cash and cash equivalents and CHF 47.6 million of short-term financial assets. That compares with CHF 91.4 million at December 31, 2025. The company states that the position funds operations into the fourth quarter of 2027 and that the statement excludes any further milestone payments. Revenue for the first half of 2026 was CHF 16.2 million against CHF 2.3 million a year earlier, entirely from partner arrangements: CHF 11.0 million recognised on the amended Lilly agreement and CHF 5.2 million on the Takeda arrangements. Research and development expense fell to CHF 22.2 million from CHF 32.7 million, which the company attributes to the pipeline focus programme announced in the third quarter of 2025 and to non-recurring manufacturing costs in the prior period, partly offset by CHF 1.9 million of new spending as the NLRP3 inhibitor entered Phase 1. The net loss narrowed to CHF 12.9 million from CHF 40.2 million, and the loss per share to CHF 0.13 from CHF 0.40.
The balance sheet carries one line that deserves attention before any judgement about equity. Total liabilities of CHF 115.2 million include CHF 89.5 million of short-term deferred contract revenue and CHF 0.8 million of long-term deferred contract revenue. Deferred revenue includes the unrecognised portion of the $100.0 million Takeda upfront received in May 2024, but the entire deferred balance is not cash already collected. Note 3.1 also includes CHF 6.4 million associated with the April 2026 milestone that was still outstanding in accounts receivable at June 30. Revenue recognition follows the performance of the contractual work; collection and recognition are separate events. Interim financial statements, note 3.1. Shareholders’ equity of CHF 35.2 million therefore understates the funded position, while the accumulated deficit of CHF 450.4 million records what it has cost to get here.
Merlintrader framing: The verified part is the regulatory step and the balance sheet: Fast Track and IND clearance dated August 11, 2026, CHF 75.4 million of cash resources at June 30, a stated runway into the fourth quarter of 2027, and a half-year loss of CHF 12.9 million supported by CHF 16.2 million of partner revenue. The September 23 week-100 release adds positive primary-endpoint findings, but does not establish clinical efficacy or quantitatively confirm the earlier biomarker separation. The unresolved questions are the final Part 2 design, subsequent clinical evidence and permanent leadership, since the chief executive seat has been held on an interim basis since the annual general meeting of June 11, 2026.
VacSYn Part 1 met its primary safety, tolerability and immunogenicity endpoints at week 100. The 34-patient dataset supports further investigation, while biomarker and clinical findings remain exploratory. Part 2 is intended to assess clinical activity before a Phase 3 decision.
The announcement of August 11, 2026 contains two separate regulatory acts that are easy to conflate. Reading them apart is the difference between understanding the news and repeating a headline.
The August 11 IND clearance allows the planned expansion of VacSYn to US sites. It does not establish that those sites have opened or enrolled patients. The registry version posted October 1, 2026 still lists twelve European sites and no US location; that record, now later than the regulatory announcement, does not independently confirm US activation. ClinicalTrials.gov, version posted October 1, 2026.
Fast Track is granted to programmes intended to treat a serious condition where non-clinical or clinical data demonstrate the potential to address an unmet medical need. What it confers is process: more frequent meetings and written communication with the review division, eligibility for rolling review of a marketing application, and eligibility to be considered for accelerated approval and priority review if the relevant criteria are met at the time of submission. What it does not confer is any conclusion about efficacy, any reduction in the evidentiary standard, or any acceleration of the trial itself. Designations are also revocable if a programme no longer meets the criteria.
The company’s own framing is consistent with that reading. The release states that the designation “reflects the early interim Phase 2 data demonstrating safety, tolerability and immunogenicity, and providing first signals that targeting underlying a-syn pathology with an active immunotherapy could potentially impact PD”. The word doing the work in that sentence is “signals”. Interim results reported at 76 weeks met their immunogenicity targets with a 100% responder rate and showed no clinically relevant safety issues; the efficacy language throughout has been about trends and stabilisation, not about a met endpoint.
The two regulatory steps were announced together. Neither establishes an agreed registrational design or a specific readout date. The H2 2026 Part 1 readout was delivered on September 23. The next FDA discussions concern the Part 2 expansion design and are expected in early 2027; this is not an agreed registrational plan.
The distinction that gets lost in coverage: Fast Track designation is granted on the basis of a plausible case for an unmet need. It has been granted thousands of times, to programmes that later succeeded and to programmes that later failed. Reading it as a statement about the probability of approval is a category error. The IND clearance, which attracts less attention, is the part with an immediate operational consequence, because it changes where the trial can enrol.
AC Immune has no approved product, no product revenue and no commercial organisation. Its entire income statement is partner money: upfront payments, milestones and research funding recognised over the periods in which the associated work is performed. That makes the revenue line lumpy in a way that a reader used to commercial companies can misread. Revenue rose from CHF 2.3 million to CHF 16.2 million between the first halves of 2025 and 2026, an increase of more than six times, and none of it reflects demand for anything.
Contract revenue for the six months ended June 30, 2026, by counterparty.
About $20.0 million at the August 11, 2026 rate. The comparable half of 2025 produced CHF 2.3 million. AC Immune has never sold a product.
Source: AC Immune half-year 2026 release and interim financial statements, SEC Form 6-K, August 5, 2026.
Two technology platforms sit underneath the pipeline. SupraAntigen is the active immunotherapy platform: short peptide antigens presented in a way designed to raise antibodies against a specific conformation of a misfolded protein while avoiding a T-cell response against the normal form. Morphomer is the small-molecule platform: brain-penetrant compounds designed to bind pathological protein aggregates inside the cell, where an antibody cannot reach. The distinction matters because the two platforms address the same targets from opposite sides of the cell membrane, and the company has partnered the Alzheimer’s applications of both while keeping the Parkinson’s applications.
ACI-7104 is the anti-alpha-synuclein active immunotherapy in Phase 2 for early Parkinson’s disease, and it is the reason most people look at this company. The optimised formulation carries the fuller designation ACI-7104.056 in trial documents; the August 2026 releases use the shorter ACI-7104 for the same candidate.
ACI-19764 is the wholly owned NLRP3 inhibitor. Its preliminary readout has occurred; see the updated development section below for the remaining milestones.
ACI-19626 is a first-in-class positron emission tomography tracer for TDP-43, the protein that aggregates in the great majority of amyotrophic lateral sclerosis cases and in a substantial share of frontotemporal dementia. Preliminary Phase 1 results presented in 2026 showed increased uptake in the brains of patients with ALS. A tracer is not a therapy, but a validated TDP-43 imaging agent would be the first way to see that pathology in a living patient, which is a prerequisite for running efficient trials in those diseases.
An earlier-stage small-molecule programme against intracellular alpha-synuclein is described as advancing towards the clinic, with a lead declaration guided to the second half of 2026.
The pipeline focus initiative announced in the third quarter of 2025 is visible in the numbers rather than described in them. Research and development expense fell by CHF 10.5 million year on year in the first half, of which the company attributes approximately CHF 4.9 million to lower personnel and operational spend as a direct result of that initiative and CHF 5.8 million to lower clinical programme spend, including active immunotherapy manufacturing costs that did not recur. General and administrative expense fell from CHF 8.3 million to CHF 7.7 million for the same reason. A company that cuts its research spending by a third while it prepares the next stage of its lead program is making a deliberate choice about where its remaining francs go.
VacSYn is registered as NCT06015841. The version posted October 1, 2026, submitted September 28, lists the study as active, not recruiting, with an actual start on July 24, 2023 and estimated primary and study completion in June 2028; the registry version available on September 5, 2026 showed January 2028. Those whole-study estimates are distinct from the Part 1 week-100 results reported September 23, 2026. The following registered design predates the forthcoming FDA discussion of Part 2.
The October 1 registry describes Parts 1 and 2 with screening of up to eight weeks, a 74-week double-blind treatment period and 26 weeks of post-treatment follow-up. Part 1 may include up to three cohorts of up to 32 participants each, with up to 24 on active treatment and eight on placebo, a 3:1 ratio. One Part 1 cohort may expand into Part 2 to reach up to 150 participants overall; when expanded beyond 32, the active/placebo ratio is adjusted to 2:1. One Part 1 cohort may also enter an extension with up to four weeks of rescreening, 52 weeks of double-blind treatment and 26 weeks of follow-up. Administration is intramuscular. These are registered design limits and estimated enrollment, not confirmation that all cohorts have opened or all 150 participants have been treated. ClinicalTrials.gov, version posted October 1, 2026.
Eligibility is narrow, which is deliberate in a disease-modification study and consequential for how the results should be read. Patients must have clinically established early Parkinson’s disease under the modified Movement Disorder Society criteria with motor symptoms present for no more than two years at screening, be aged between 40 and 75, be at modified Hoehn and Yahr stage I or II, and be on levodopa monotherapy at 300 mg per day, stable for three months before baseline. A screening DaT-SPECT scan read centrally must be consistent with Parkinson’s disease. Known carriers of PRKN, PINK1, DJ1 and LRRK2 mutations are excluded, as are patients with a history of freezing episodes or falls, and patients who have used dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine or anticholinergics for more than ninety days in total or within ninety days of baseline.
The registered primary outcomes cover safety and immunogenicity. For Parts 1 and 2, the October 1 record gives week 100 for adverse events, abnormal MRI findings, clinically significant physical and neurological examination changes, suicidal ideation or behaviour assessed with the Columbia scale, and alpha-synuclein-specific serum antibody titres. Corresponding extension outcomes use week 78. Secondary outcomes include alpha-synuclein-related biofluid biomarkers, DaT-SPECT dopamine transporter measures and change from baseline in MDS-UPDRS Part III; motor and non-motor function on the full MDS-UPDRS appears among other outcomes. These outcome schedules differ from the 74-week treatment period and from the dates or sample sizes of company-reported interim analyses. They do not turn safety and immunogenicity into established clinical efficacy. ClinicalTrials.gov, version posted October 1, 2026.
That hierarchy is the single most important structural fact about this readout. A Phase 2 study whose primary endpoints are safety and antibody titres can succeed on its own terms while telling the market very little about whether patients do better, and it can equally show a promising clinical trend that is not statistically powered to mean anything. Both outcomes are possible in the same data set, and the company has been consistent in describing the clinical measures as trends.
The October 1, 2026 registry version lists twelve sites in Germany, Spain and the United Kingdom. No US site is listed in that version. US expansion following the August IND clearance remains a company-announced plan; the checked record does not establish US operational activation. Its estimated June 2028 primary and study completion dates are whole-study estimates, separate from the Part 1 results already reported September 23. ClinicalTrials.gov, version posted October 1, 2026.
The company reported results from all 34 randomized patients: 25 received ACI-7104 and nine placebo. All treated patients developed antibodies against the immunizing PD01 antigen after three immunizations. Antibodies also reacted with aggregated alpha-synuclein, with penetration into cerebrospinal fluid reported.
ACI-7104 was generally safe and well tolerated through week 100. The release describes a CSF total alpha-synuclein signal consistent with target engagement and exploratory correlations between antibody levels and disease-activity measures. These observations do not demonstrate slowed Parkinson’s progression. The announcement does not supply a quantitative clinical treatment effect or a new numerical adverse-event breakdown; the week-76 figures below remain historical.
Part 1 continues in a two-year extension. The final Part 2 expansion design is still being consolidated for FDA review, with meetings expected in early 2027. Initiation of Part 2 and entry into Phase 3 are not established by this release. Company announcement, September 23, 2026.
The interim analysis reported on December 11, 2025 is the evidentiary base for everything that has happened since, including the Fast Track grant. It covered Part 1, which randomised 34 patients three to one. All participants in the analysis had been treated for at least twelve months, and twenty of them for up to eighteen months, which is the 74-week mark.
All target criteria were met. The responder rate was 100%. At week 76, two weeks after the sixth immunisation, antibody titres in serum were more than 500-fold higher than in the placebo group, and antibody responses to both the immunising peptide and the native alpha-synuclein peptide were boosted after each dose from the second immunisation onward, while the placebo group showed no detectable signal. Titres in cerebrospinal fluid rose with successive immunisations and average IgG levels in CSF were also more than 500-fold higher than placebo, which is the evidence that the antibodies cross the blood-brain barrier. Changes from baseline in CSF antibody concentration correlated with changes in serum titres, with a Spearman coefficient of 0.92 at week 24 and 0.85 at week 76, both at p below 0.05.
Total alpha-synuclein in cerebrospinal fluid stabilised in the treatment arm while declining in the placebo arm, with a post-hoc p value of 0.018. The company’s explanation is that antibody binding stabilises the target or increases clearance from the brain, whereas untreated progression sees alpha-synuclein accumulate in tissue and fall in CSF. Neurofilament light chain, a general marker of neuronal damage, remained stable in the treatment arm and rose in the placebo arm. Plasma glial fibrillary acidic protein and DaT-SPECT imaging were described as suggesting stabilised pathology, without figures attached.
Two qualifications belong next to those results rather than in a footnote. The alpha-synuclein CSF result is explicitly post-hoc, meaning the analysis was defined after the data were seen, which lowers its evidentiary weight regardless of the p value. And the comparison group is small: in a three-to-one randomisation of 34 patients, the placebo arm comprises nine people, as confirmed in the September 23 release, so a placebo trajectory that looks like textbook progression can also be the arithmetic of a handful of patients.
At week 74 the treated group showed no meaningful progression in mean total score or change from baseline on Part III of the MDS-UPDRS, while the placebo arm increased as expected in normal disease progression. Stratifying by levodopa on and off state, the difference between the arms was described as further enhanced. The company’s own word for this is “suggestive of a trend for stabilization”, and Professor Werner Poewe, quoted in the release as an outside expert, described the consistency of the trends as promising and the findings as fully supporting further development, language that stops well short of a claim of efficacy.
No clinically relevant or serious adverse events considered related to the study drug had been reported at weeks 50 and 76. The most common adverse events were transient injection-site reactions in 56% of patients, headache in 15% and fatigue in 12%. For an active immunotherapy, that profile is the point: the historical fear with alpha-synuclein vaccines is an autoimmune reaction against the normal protein, and nothing of that kind has appeared.
Active immunisation aims to generate the patient’s own antibody response; passive immunotherapy administers antibodies directly. Differences in exposure and dosing do not establish superiority. VacSYn’s small interim analysis cannot determine whether this approach improves clinical outcomes or outperforms another program.
The honest summary of the interim: the immunogenicity result is strong, replicated across serum and CSF, and statistically supported. The biomarker result is directionally consistent but partly post-hoc and drawn from very small groups. The clinical result is a trend in a study that was never powered to detect a clinical effect. Fast Track designation is consistent with all three of those statements being true at once.
The NLRP3 inflammasome is a protein complex inside immune cells that, when activated, drives the release of interleukin-1 beta and a broader inflammatory cascade. In the brain, chronic activation of that pathway in microglia is one of the mechanisms by which protein aggregation is thought to become neuronal damage. Inhibiting it is an approach with a wide potential application and a long history of disappointment, and several large companies have programmes in the area.
The August 20 preliminary analysis reported tolerability and CSF exposure, without serious adverse events or treatment withdrawals to date. Cardiovascular-risk cohort dosing had begun. Initial results were guided before year-end on August 20; the September 2 invitation says around year-end; full Phase 1/1b results in H1 2027. This does not establish neurological efficacy. Company release filed with SEC.
The programme is the reason research spending rose CHF 1.9 million in the first half even as the total fell, and it is the second of the two near-term catalysts management named.
TDP-43 aggregation is present in the overwhelming majority of amyotrophic lateral sclerosis cases and in a large share of frontotemporal dementia, and it is also found alongside Alzheimer’s pathology in many older brains. Unlike amyloid and Tau, it cannot currently be imaged in a living patient, which means trials in those diseases enrol on clinical grounds and cannot confirm the target is present. A first-in-class tracer would change that.
Preliminary Phase 1 results showed increased uptake in the brains of patients with ALS. That is an early and encouraging result rather than a validated tracer; the standard for imaging agents is demanding, and the path from a signal to a diagnostic used in trials is long. The commercial logic, if it works, is a partnership with an imaging company rather than a company-built business, which is how AC Immune has handled diagnostics before.
An early-stage Morphomer programme targeting alpha-synuclein inside the cell is advancing towards the clinic, with a lead declaration guided to the second half of 2026. Conceptually it is the complement to ACI-7104: antibodies raised by a vaccine act on extracellular and membrane-associated species, while a small molecule can reach aggregates inside the neuron. A company that owned both would have two shots at the same biology, which is a stronger strategic position than one.
Three partners fund the Alzheimer’s side of the pipeline. Their money is the reason the company can run a Parkinson’s programme it owns outright, and the terms are worth stating with their limits attached, because contingent milestone ceilings are the most frequently misquoted numbers in biotechnology.
Maximum contingent milestone amounts disclosed by the company, not amounts owed or expected.
Development, commercial and sales milestones under the May 2024 option and licence, plus an option exercise fee in the low-to-mid nine-figure dollar range and tiered mid-to-high teens royalties
Development, regulatory and commercial milestones under the amended agreement of April 2026, plus low double-digit tiered royalties. About $2.1B at the August 11, 2026 rate
These are contingent ceilings spread across the entire life of each agreement: particular payments depend on the relevant development, commercial or sales milestone, rather than all requiring the same approval or sales threshold. The company states more than $4.5 billion of potential milestones across all partners.
Source: AC Immune interim financial statements, Form 6-K of August 5, 2026, and the Lilly amendment announcement of April 7, 2026.
In May 2024 AC Immune signed a worldwide option and licence agreement with Takeda covering active immunotherapies targeting amyloid beta, including ACI-24.060. AC Immune received a $100.0 million upfront payment, recorded at CHF 92.3 million, and is eligible for an option exercise fee described as being in the low-to-mid nine-figure dollar range plus additional development, commercial and sales-based milestones of up to approximately $2.1 billion, equivalent to CHF 1.7 billion, if every milestone is achieved over the life of the agreement. Royalties are tiered in mid-to-high teens percentages of worldwide net sales. Takeda may terminate the agreement at any time on ninety days’ notice, a clause that belongs in any assessment of how firm this funding is.
The clinical vehicle is the Phase 1b/2 ABATE trial in prodromal Alzheimer’s disease. In February 2026 the agreement was amended to initiate a final cohort, AD4, which evaluates ACI-24 with an additional adjuvant intended to boost immunogenicity. First-patient treatment in AD4 on April 30, 2026 triggered a $12.0 million milestone, measured at CHF 9.5 million on that transaction date. During the first half, CHF 3.1 million was recognised as contract revenue and CHF 6.4 million remained deferred. The full milestone was still outstanding in accounts receivable at June 30, measured at CHF 9.8 million at that reporting date; earning the milestone did not establish receipt of the cash. Interim financial statements, note 3.1. On June 30, 2026 the company reported twelve-month interim data from the first three cohorts, covering 74 prodromal Alzheimer’s patients: generally safe and well tolerated, no evidence of amyloid-related imaging abnormalities with oedema, and anti-amyloid antibody responses detected at every dose level. The absence of ARIA-E is the differentiating claim for an active immunotherapy against a background of approved anti-amyloid antibodies where that complication is a labelled risk.
The licence and collaboration agreement dated December 11, 2018 was amended in April 2026 to extend research into new lead Tau Morphomer candidates and potential back-up compounds. AC Immune received a CHF 10.0 million upfront payment and a further CHF 1.0 million milestone in the first half of 2026 on delivery of a preclinical data package, and a subsequent milestone is tied to Phase 1 dosing. Remaining development, regulatory and commercial milestones are disclosed as over CHF 1.7 billion with tiered royalties in the low double digits. Those two payments are the CHF 11.0 million that dominates the half-year revenue line.
The phospho-Tau active immunotherapy ACI-35.030 is partnered with Janssen. The company continues to list the collaboration among its partnered Alzheimer’s programmes in the corporate description accompanying its August 2026 releases, and no new financial terms or clinical milestones for that programme were disclosed in the half-year materials.
The “more than $4.5 billion in potential milestone payments” that appears in every AC Immune release is a sum of maximum contingent amounts across agreements, dependent on the relevant development, commercial and sales milestones under each contract. It is not a receivable, not a valuation and not a forecast. Cash actually received includes the $100.0 million Takeda upfront in May 2024 and CHF 11.0 million from Lilly in the first half of 2026. The $12.0 million Takeda milestone was earned in April and was still receivable at June 30, rather than cash collected. The reported CHF 89.5 million of short-term and CHF 0.8 million of long-term deferred contract revenue therefore is not entirely unrecognised cash already received: it includes CHF 6.4 million from that outstanding milestone. Any subsequent collection needs its own dated evidence. Interim financial statements, note 3.1.
AC Immune reports in Swiss francs as a foreign private issuer, with an annual Form 20-F and updates furnished on Form 6-K. The June 30 half-year financial statements were furnished August 5. The company also released a first-quarter financial and corporate update on April 30; the half-year statement format does not reflect the frequency of all financial updates.
Six months ended June 30, in millions of Swiss francs. Negative values sit below the zero line.
The loss narrowed by CHF 27.3 million, of which CHF 13.9 million came from higher partner revenue and CHF 11.1 million from lower operating spend. Neither driver is a product.
Source: AC Immune condensed consolidated statements of income and loss, Form 6-K exhibit 99.1, August 5, 2026.
Revenue of CHF 16.2 million against CHF 2.3 million, research and development of CHF 22.2 million against CHF 32.7 million, general and administrative of CHF 7.7 million against CHF 8.3 million, and other operating income of CHF 0.1 million produce total operating expenses of CHF 29.8 million and an operating loss of CHF 13.6 million, against CHF 38.8 million a year earlier. The finance result swung from a CHF 1.5 million loss to a CHF 0.7 million gain, driven by CHF 2.9 million of higher foreign exchange gains partly offset by CHF 0.7 million less interest income on short-term financial assets. There is no income tax charge. The loss for the period is CHF 12.9 million, or CHF 0.13 per share on 101,963,177 weighted average shares.
Position at June 30, 2026, as disclosed in the going-concern note.
Down from CHF 91.4 million at December 31, 2025. The company states this funds operations into Q4 2027, excluding potential milestone payments.
Source: AC Immune interim condensed consolidated financial statements, note 2, Form 6-K of August 5, 2026.
The company’s own words are that cash resources “are expected to provide sufficient capital to last into Q4 2027, excluding potential milestone payments”. The going-concern note states separately that the company believes it can meet its obligations for at least twelve months from the filing date after considering CHF 27.8 million of cash and CHF 47.6 million of short-term financial assets.
Total cash resources in millions of Swiss francs, as reported at each date.
Cash resources fell CHF 16.6 million between December and March, then increased CHF 0.6 million between March and June; these balance changes are not operating cash burn. The Lilly payments supported the first-half funding position. Takeda’s $12.0 million milestone was earned on April 30, but remained an outstanding receivable of CHF 9.8 million at June 30, so it was not cash received in the second quarter. Interim financial statements, note 3.1.
Source: AC Immune quarterly and half-year releases, Forms 6-K of April 30 and August 5, 2026.
Cash-resource movements include partner receipts, operating spending and other cash flows. The CHF 16.6 million Q1 reduction and broadly stable Q2 position are not a constant quarterly burn rate. Management’s runway estimate is conditional on its operating assumptions; trial expansion, spending changes or financing can alter it.
Total assets are CHF 150.4 million, of which CHF 50.4 million is an intangible asset carried unchanged from December 31, 2025, CHF 47.6 million short-term financial assets, CHF 27.8 million cash, CHF 9.9 million accounts receivable that were nil at year end, and CHF 4.4 million of prepaid expenses. Total liabilities are CHF 115.2 million, of which CHF 89.5 million is short-term deferred contract revenue and CHF 0.8 million long-term deferred contract revenue, CHF 9.1 million net employee defined benefit liabilities, CHF 7.1 million accrued expenses, CHF 4.1 million of lease liabilities across current and non-current, and CHF 3.1 million of deferred income. Shareholders’ equity is CHF 35.2 million against CHF 44.9 million at year end, with share premium of CHF 483.6 million and accumulated losses of CHF 450.4 million.
A reader who sees CHF 115.2 million of liabilities against CHF 150.4 million of assets and concludes the company is heavily indebted has misread the largest line. AC Immune has no bank debt, no convertible notes and no term loan. The CHF 89.5 million of short-term deferred contract revenue includes amounts from partner advances as well as CHF 6.4 million associated with the Takeda milestone still receivable at June 30. It is not wholly partner cash already banked. Contract revenue is recognised as the agreed work is performed; this accounting liability is distinct from bank borrowing and from collection of the outstanding milestone. Interim statements, note 3.1. The defined benefit pension liability of CHF 9.1 million is a Swiss employer obligation, real but long-dated. The genuine claims on cash in the next twelve months are the CHF 1.5 million of trade payables, CHF 7.1 million of accrued expenses and CHF 0.8 million of current lease liabilities.
The company-declared share count is 101,742,231 shares outstanding at December 31, 2025, stated on the cover of the Form 20-F filed on March 13, 2026. The equivalent figures were 100,410,377 at December 31, 2024 and 99,197,829 at December 31, 2023, so the count has grown by roughly 1.3% a year over two years. For a clinical-stage company with no product revenue, that is a remarkably quiet share register, and it is a direct consequence of the partnering strategy: the Takeda upfront of $100.0 million in May 2024 is money that did not have to be raised from shareholders.
The half-year statements do not restate a point-in-time outstanding count at June 30, 2026. What they do give is the weighted average used for the loss per share, 101,963,177 shares for the six months against 100,519,884 a year earlier, and the treasury position, which fell from 10,899,773 shares at December 31, 2025 to 10,673,993 at June 30, 2026. Share capital at par rose from CHF 2,253 thousand to CHF 2,263 thousand and share premium from CHF 481.9 million to CHF 483.6 million. Proceeds from the sale of treasury shares in public offerings, net of fees, were CHF 0.6 million in the period. Treasury shares are already issued shares held by the company; their sale can affect shares held by outside investors. They should not be equated with an unused authorisation to issue new shares.
An at-the-market programme with Jefferies LLC exists and is described in note 12 of the 2025 Form 20-F. The half-year statements refer to it only by cross-reference and disclose no at-the-market activity for the first half of 2026. That is a fact worth holding lightly: the absence of disclosed usage in a six-month interim statement is not the same as a commitment not to use it, and a company planning further Phase 2 development with management-estimated funding into the fourth quarter of 2027 has an obvious reason to keep the facility available.
An equity raise would add shares according to the proceeds sought, issue price and transaction costs. The older August 11 illustration was not a financing plan. This analysis assumes no new raise; partnership receipts and treasury-share sales work through different mechanics and depend on their actual terms.
Where the funding could come from without shareholders: an option exercise by Takeda on ACI-24, described as a fee in the low-to-mid nine-figure dollar range; the Phase 1 dosing milestone under the amended Lilly agreement; a new partnership on ACI-7104 itself, which is currently wholly owned and unpartnered; or a further grant of the kind received in June 2026, when the Vijay and Marie Goradia Charitable Foundation committed $4 million to extend Part 1 of VacSYn by two years. These sources have different contractual status: the June grant was announced, while future options, milestones and new partnerships depend on further events. Management’s runway statement explicitly excludes potential milestone payments; it does not state that the announced June grant is excluded.
Andrea Pfeifer retired as CEO at the June 11, 2026 AGM following the May announcement. Board chair Martin Zügel is serving as interim CEO; the September 23 release still identifies him in that role. Leadership transition matters for development and financing decisions, but does not by itself establish a change in strategy.
The situation is worth weighing without dramatising it. A founder-led company that loses its founder after two decades faces a genuine transition, and the chair stepping into the executive seat is a common bridging arrangement that also concentrates board and management roles in one person for its duration. What makes the timing consequential here is what falls inside it: the September 23 VacSYn Part 1 readout and the planned early-2027 regulatory discussions of the Part 2 design, and any decision about partnering ACI-7104 or financing the company through 2027. Those are the decisions a permanent chief executive would normally own.
The counter-argument is equally factual. The strategy that produced the current position, meaning the pipeline focus initiative of the third quarter of 2025 and the partnering of the Alzheimer’s assets, was set before the transition and is visibly being executed: research spending down a third, the Takeda amendment signed in February 2026 and the Lilly amendment signed in April 2026, a regulatory package delivered in August. Continuity of execution is visible in the filings; continuity of leadership is not yet settled.
Finviz data as of October 2, 2026: market capitalization 285.98M USD; shares 91.10M, float 62.57M, short float 5.55% (3.48M shares short), short ratio 17.14; institutional ownership 24.30%, insider ownership 38.52%. The previous regular-session close was $2.81 on October 1. Third-party figures can lag underlying filings; the data date is not the short settlement date. The third-party share count is distinct from dated SEC share counts. Ownership reports may overlap and do not form an exclusive allocation of the capital. Finviz.
ACIU is a small biotechnology company whose share price can react sharply to clinical news and financing. Its Swiss-franc accounts add currency effects for dollar-based comparisons. Near-term clinical guidance is expressed in windows, so an exact trading date cannot be inferred from the published schedule.
Cash and financial assets are balance-sheet resources consumed in development; they are not a floor under the share price. The historical dollar equivalents elsewhere use the explicitly dated August 11 exchange rate. Intangible assets are accounting carrying values, not estimates of sale proceeds.
Retail discussion reflects opinion and attention; it does not establish a clinical result, regulatory approval or commercial demand.
Stocktwits data as of October 2, 2026. On Stocktwits, the normalized sentiment score for $ACIU was 35 out of 100, classified by the service as bearish, with normalized message activity of 56 out of 100 in the high band and 3,849 watchers. These are separate platform metrics: the score is not the percentage of bearish messages and the activity score is not a count of individual posts. The official one-month sentiment series shows 39 on September 2, 65 on September 23, 67 on September 28, 46 on September 30 and 36 on October 1. Its October 2 entry is also 36 in this retrieval, while the live pulse is 35; the two views are snapshots with different update timing, not two contradictory clinical facts.
The retrieved sample contains ten posts dated September 25 through October 2. Within that sample, constructive opinions include a belief that the company is undervalued relative to its partnerships and possible milestone payments, and speculation that another licensing transaction might be announced. Other posts relay company news or trial-registry links rather than present an independent analysis. These views are trader opinions from a small displayed sample, not evidence of a new agreement, an approach by a potential buyer or future revenue. They also do not establish the views of every watcher or the balance of discussion across other platforms.
One factual item circulated in the stream on October 1. The ClinicalTrials.gov record of VacSYn, NCT06015841, was updated, with the new version submitted September 28 and posted October 1, 2026. It lists the study as active, not recruiting, with an estimated enrollment of 150 participants for the whole study and estimated primary and study completion in June 2028, later than the January 2028 shown by the registry version available on September 5. Registry estimates are not company guidance and do not date a readout.
The displayed sample includes a post on October 2 reporting Tom Graney’s election to the board and an October 1 post linking to the VacSYn registry update. Those are examples of news circulating in this specific Stocktwits sample. Their presence does not measure how much discussion the extraordinary general meeting generated overall, and this snapshot does not provide a verified comparative sample of X or Reddit. The company announcement and trial record, rather than the number or tone of reposts, remain the sources for the underlying events.
The September 23 results strengthen the safety and immunogenicity basis for continued development of ACI-7104. They do not turn the December 2025 exploratory biomarker and clinical trends into confirmed efficacy. The full Part 1 dataset includes 25 treated patients and nine placebo recipients. Part 2 is intended to assess clinical activity before any Phase 3 decision; its final design and timing remain to be established with FDA input. Partner funding supports the broader pipeline, while cash runway remains an estimate conditional on spending and development plans.
What is verified. Fast Track designation and IND clearance for ACI-7104 in early Parkinson’s disease, announced August 11, 2026 and furnished on Form 6-K the same day. Interim Part 1 results at week 76 in 34 randomised patients: 100% immunogenicity responder rate, serum and CSF antibody titres more than 500-fold above placebo, Spearman correlation between compartments of 0.92 at week 24 and 0.85 at week 76, CSF alpha-synuclein stabilisation with a post-hoc p of 0.018, stable neurofilament light against a rising placebo arm, no clinically relevant drug-related serious adverse events, injection-site reactions in 56% of patients. Cash resources of CHF 75.4 million at June 30, 2026, about $93.0 million, composed of CHF 27.8 million cash and CHF 47.6 million short-term financial assets, funding operations into Q4 2027 on the company’s own statement and excluding milestone payments. First-half revenue of CHF 16.2 million, all from Lilly and Takeda, against CHF 2.3 million a year earlier. Research and development of CHF 22.2 million, down from CHF 32.7 million. Net loss of CHF 12.9 million, CHF 0.13 per share. 101,742,231 shares outstanding at December 31, 2025 per the Form 20-F, and 10,673,993 treasury shares at June 30, 2026.
What remains unproven is clinical benefit and reproducible disease modification. The September 23 release does not provide a numerical week-100 clinical effect or a new p value confirming the historical week-76 analysis. It does establish that the reported dataset is week 100; the older week-104 wording is no longer the current description. FDA agreement on the final Part 2 design, its start date and a subsequent Phase 3 decision remain pending. The point-in-time share count at June 30 and any subsequent ATM usage cannot be inferred from weighted averages or older third-party data. Permanent CEO selection and individually verified analyst notes remain separate open questions.
The current development windows are listed in the catalyst section. They are company guidance, not guaranteed dates. The stated Q4 2027 funding horizon is an estimate rather than a fixed date on which cash becomes zero.
The company’s Form 6-K dated and filed October 2, 2026, accession 0001651625-26-000023, confirms that AC Immune held its Extraordinary General Meeting and that shareholders approved Tom Graney’s election as a member of the Board of Directors until the end of the Annual General Meeting in 2027. The earlier invitation described a proposal; this filing reports the final outcome of that agenda item. Read the official filing.
The same filing states that further details will be included in minutes to be published on the company’s website within 15 days. It supplies no number of shares voted, percentage of support or quorum figure. Those values are not inferred from the approval. The prior invitation also described an intended Audit and Finance Committee appointment subject to election. The October 2 result confirms the board election; it does not separately document that the committee appointment has already taken effect. Form 6-K, October 2.
The filing is signed by interim CEO Martin Zuegel and CFO Christopher Roberts. It does not announce a permanent chief executive, amend the development timetable, report a new treatment effect or supply a fresh cash balance. The governance outcome therefore closes the voting-status question while leaving the separate clinical and financial questions attached to their own sources and dates. The September 23 VacSYn dataset and June 30 financial position remain the dated references discussed elsewhere in this hub. Source and signatures.
Going forward, the useful governance evidence will be the published minutes and any subsequent company disclosure about board responsibilities or permanent leadership. The clinical questions remain Part 2 design, FDA discussions and reproducible clinical activity. Neither a board election nor an announcement of future discussions establishes an agreed registrational path, a trial start or marketing approval. This distinction prevents a completed corporate meeting from remaining on the page as an upcoming catalyst and prevents its result from being read as a clinical milestone. Documented scope of the meeting result.
Week-100 results from Part 1 of the Phase 2 trial of ACI-7104 in early-stage Parkinson’s disease. All three primary endpoints — safety, tolerability and immunogenicity — were met. All 34 randomised patients are included, 25 on ACI-7104 and 9 on placebo. 100% of treated patients developed antibodies against the immunising target antigen PD01 after three immunisations, with robust antibody penetration into the cerebrospinal fluid in all patients.
No, and the company does not claim it. Part 1 was not designed to evaluate biomarkers or clinical outcomes. A signal on total a-syn in the cerebrospinal fluid and correlation trends between antibody levels and disease-activity measures were reported as exploratory analyses on a limited sample. Part 2 is the part designed to provide evidence of clinical activity as the basis for a Phase 3 decision.
Total cash resources of CHF 75.4 million at June 30, 2026, made up of CHF 27.8 million in cash and equivalents and CHF 47.6 million in short-term financial assets, against CHF 91.4 million at December 31, 2025. The company states these resources are expected to fund operations into the fourth quarter of 2027.
From partnerships rather than from products. A $12 million milestone from Takeda was triggered by the initiation of the Alzheimer’s disease AD4 cohort in the ABATE trial in the first half of 2026, and the Morphomer small-molecule Tau programme is partnered with Lilly. AC Immune has no approved product, no product revenue and no commercial organisation.
No. This Stock Hub is informational and educational. It sets out dated facts, their sources and the scenarios they leave open. It does not recommend any action.
Yes. The October 2 Form 6-K confirms that shareholders approved Tom Graney’s election to the Board of Directors until the end of AGM 2027. Minutes are to be published within 15 days; no vote tally is supplied in that filing. Official source.
The result filing reports the board-election outcome. It supplies no new clinical result, permanent CEO appointment or updated cash balance. Those questions require their own dated disclosures and remain separate from the completed EGM. Official source.
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Join @merlintraderpub_com on TelegramDisclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ACIU or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, the ClinicalTrials.gov registry and market-data providers, and are stated with their reference dates. AC Immune SA reports in Swiss francs; dollar equivalents shown here use an exchange rate of CHF/USD 1.2336 as at August 11, 2026 and will move with the currency. Data can change without notice and figures published before a corporate release become outdated the moment that release is issued. Readers should verify every figure against the primary source before acting on it.
Biotechnology companies carry risks that do not apply to most other sectors. Clinical trial outcomes are binary and cannot be predicted from earlier-stage results; interim data from a small cohort can fail to replicate in a larger or longer analysis, and a positive Phase 2 signal can be followed by a failed Phase 3. Regulatory designations such as Fast Track confer procedural advantages only: they are not a statement about efficacy, they do not lower the evidentiary standard for approval, and they can be rescinded. Companies at this stage of development frequently need to raise capital on terms that dilute existing shareholders, and they can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser before acting.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
